Zhongjian Wang
Biographic Data
| ID | 10030655 |
|---|---|
| NAME | Zhongjian Wang |
| GIVEN NAMES | Zhongjian |
| FAMILY NAME | Wang |
| SIGNATURE | WANG Z |
| ORCID | 0000-0002-4946-969X |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China
Background As China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern. Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet comparably effective treatments. Encouragingly, China launched its abbreviated biosimilar pathway in 2015, and since then, a large number of biosimilars h…
The nomograms for predicting overall and cancer-specific survival in elderly patients with early-stage lung cancer
Purpose: Lung cancer is the leading cause of death from cancer and the number of operable elderly lung cancer patients is increasing, with advanced age being associated with a poorer prognosis. However, there is no easy and comprehensive prognostic assessment method for these patients. Methods: = 6,231) were used for external validation. Two nomogram prognostic models were created after independent prognostic factors connected to both overall sur…
No prominent works on this page.
The nomograms for predicting overall and cancer-specific survival in elderly patients with early-stage lung cancer
Purpose: Lung cancer is the leading cause of death from cancer and the number of operable elderly lung cancer patients is increasing, with advanced age being associated with a poorer prognosis. However, there is no easy and comprehensive prognostic assessment method for these patients. Methods: = 6,231) were used for external validation. Two nomogram prognostic models were created after independent prognostic factors connected to both overall sur…
Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China
Background As China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern. Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet comparably effective treatments. Encouragingly, China launched its abbreviated biosimilar pathway in 2015, and since then, a large number of biosimilars h…
Internal Medicine (2 works) · Medicine (2 works) · Biology (1 works) · Biosimilar (1 works) · Biosimilars and Bioanalytical Methods (1 works) · Cancer (1 works) · China (1 works) · Computer Science (1 works) · Database (1 works) · Environmental health (1 works)